A1CLJ

17-(cyclopropylmethyl)-3,14-dihydroxy-5alpha-4,5-epoxymorphinan-6-one

Created:2025-08-01
Last modified:  2026-03-04
Find related ligands:
Help
Chemical Details
Formal Charge0
Atom Count48
Chiral Atom Count4
Bond Count53
Aromatic Bond Count6
2D diagram of A1CLJ
Toggle HydrogenToggle Labels
Chemical Component Summary
Name17-(cyclopropylmethyl)-3,14-dihydroxy-5alpha-4,5-epoxymorphinan-6-one
Systematic Name (OpenEye OEToolkits)(4~{R},4~{a}~{S},7~{a}~{R},12~{b}~{S})-3-(cyclopropylmethyl)-4~{a},9-bis(oxidanyl)-2,4,5,6,7~{a},13-hexahydro-1~{H}-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
FormulaC20 H23 N O4
Molecular Weight341.401
TypeNON-POLYMER
Chemical Descriptors
TypeProgramVersionDescriptor
SMILESACDLabs14.52O=C1CCC2(O)C3Cc4ccc(O)c5OC1C2(CCN3CC1CC1)c54
SMILESCACTVS3.385Oc1ccc2C[CH]3N(CC[C]45[CH](Oc1c24)C(=O)CC[C]35O)CC6CC6
SMILESOpenEye OEToolkits3.1.0.0c1cc(c2c3c1CC4C5(C3(CCN4CC6CC6)C(O2)C(=O)CC5)O)O
Canonical SMILESCACTVS3.385 Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC6CC6
Canonical SMILESOpenEye OEToolkits3.1.0.0 c1cc(c2c3c1C[C@@H]4[C@]5([C@]3(CCN4CC6CC6)[C@@H](O2)C(=O)CC5)O)O
InChIInChI1.06 InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
InChIKeyInChI1.06 DQCKKXVULJGBQN-XFWGSAIBSA-N
Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank IDDB00704 
NameNaltrexone
DescriptionDerivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Synonyms
  • Naltrexonum
  • 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
  • 17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
  • Naltrexon
  • N-Cyclopropylmethyl-14-hydroxydihydromorphinone
IndicationUsed as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
Categories
  • Agents Causing Muscle Toxicity
  • Alcohol Deterrents
  • Alimentary Tract and Metabolism
  • Alkaloids
  • Analgesics
ATC-Code
  • N02AA56
  • N07BB04
  • A08AA62
CAS number16590-41-3

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Mu-type opioid receptorMDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRT...unknownantagonist
Kappa-type opioid receptorMDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLE...unknownantagonist
Delta-type opioid receptorMEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAI...unknownantagonist
Sigma non-opioid intracellular receptor 1MQWAVGRRWAWAALLLAVAAVLTQVVWLWLGTQSFVFQREEIAQLARQYA...unknown
UDP-glucuronosyltransferase 1-1MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL19019
PubChem 5360515
ChEMBL CHEMBL19019
ChEBI CHEBI:7465